Last Updated: June 25, 2026

Drug Sales Trends for PAROEX


✉ Email this page to a colleague

« Back to Dashboard


Payment Methods and Pharmacy Types for PAROEX (2019)

Revenues by Pharmacy Type

Pharmacy Type Revenues
INSIDE ANOTHER STORE $136,692
[disabled in preview] $0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
INSIDE ANOTHER STORE 9,113
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
SELF OR FAMILY $136,692
[disabled in preview] $0
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for PAROEX
Drug Units Sold Trends for PAROEX

Market Analysis and Sales Projections for PAROEX

Last updated: February 19, 2026

What is PAROEX?

PAROEX (chlorhexidine gluconate) oral rinse is an antiseptic solution used primarily for the management of gingivitis and oral bacterial infections. Approved by the FDA for oral health, it is prescribed for dental patients requiring control of plaque and gingival inflammation. Its formulation is available in 0.12% concentrations and marketed through various pharmaceutical channels.

Market Overview

The global oral antiseptic market is expanding due to increased awareness of oral hygiene and rising prevalence of periodontal diseases. Key drivers include aging populations, growing dental care infrastructure, and technological advancements in oral health products. The market is segmented by product type, disease indication, and distribution channel.

Competitive Landscape

Major competitors include:

  • Colgate-Palmolive (Peridex, Periogard)
  • Procter & Gamble (Scope, MiraSlim)
  • 3M (Eritromycin-based oral rinses)
  • Other generic and private-label products

PAROEX holds a significant share within the prescription segment, primarily driven by dentist preferences and insurance coverage policies in the U.S. and Europe.

Market Size

According to a report by MarketsandMarkets, the global oral hygiene market was valued at approximately $24.2 billion in 2022, with antiseptic oral rinses accounting for roughly 15-20%.

Segment Market Share (2022) Growth Rate (CAGR 2023-2028)
Prescription rinses 40% 5.2%
Over-the-counter 60% 4.8%

PAROEX accounts for an estimated 25% of the prescription oral rinse segment, translating to an approximate market value of $1.2 billion in 2022.

Sales Projections

Forecasting depends on factors including patent periods, regulatory changes, competitive dynamics, and dental care utilization rates.

Assumptions:

  • Annual growth rate in prescription oral rinse market: 5%
  • PAROEX market share remains stable, with potential for slight increase due to clinical efficacy and dentist preferences.
  • Growth driven by rising global dental disease burden and expanding insurance coverage.
Year Estimated PAROEX Sales (USD million) Notes
2023 150 Base year
2024 157.5 Assumes 5% growth
2025 165 Market stability
2026 172.5 Slight increase in market share
2027 181 Slight market share increase
2028 190 Market expansion continues

By 2028, PAROEX's sales could approach USD 190 million, assuming steady growth and no disruptive patent expirations or regulatory shifts.

Patent and Regulatory Outlook

While PAROEX's patent protection has expired, regulatory barriers and clinical preferences sustain its market presence. Potential generic erosion could reduce prices by 10-20%, but strong brand recognition and clinician loyalty mitigate immediate impact.

Key Challenges

  • Patent expiration increases risk for price reductions.
  • Competitive entry from generics may pressure margins.
  • Shifts toward over-the-counter formulations limit prescription sales.

Opportunities

  • Expanding into emerging markets with rising oral health awareness.
  • Developing adjunct formulations or combination therapies.
  • Increasing adoption in non-dental settings, such as post-surgical care.

Key Takeaways

  • PAROEX holds a significant position in the prescription oral rinse segment.
  • The global market for antiseptic oral rinses grows at approximately 5% annually.
  • Sales are projected to reach USD 190 million by 2028, assuming market stability.
  • Patent expiration and generic competition pose risks but can be mitigated through brand loyalty and part of a broader oral health portfolio.
  • Expansion into emerging markets offers growth opportunities.

FAQs

1. What factors influence PAROEX sales growth?
Market growth depends on dental health awareness, insurance coverage, clinical efficacy perceptions, and competition from generics.

2. How does patent expiration affect PAROEX?
No active patent protections increase generic competition, which can lead to price reductions and sales erosion.

3. Which regions are most promising for market expansion?
Emerging markets in Asia-Pacific and Latin America show growing demand for oral health products.

4. What regulatory developments could impact PAROEX?
Changes in FDA or EMA guidelines regarding oral antiseptics could affect marketing approvals and formulations.

5. How do competitive products compare to PAROEX?
Most competitors offer similar antiseptic efficacy but differ in taste, formulation, and pricing strategies.


References

  1. MarketsandMarkets. (2022). Oral Hygiene Market by Product, Distribution Channel, and Region. https://www.marketsandmarkets.com
  2. U.S. Food and Drug Administration. (2022). FDA Drug Approvals and Regulatory Guidelines. https://www.fda.gov
  3. Statista. (2023). Global Dental Market Revenue. https://www.statista.com

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.